Glaxo aims for HIV cure by 2030 as it looks to post-split future

Glaxosmithkline told investors it’s aiming to develop a cure for HIV by 2030, as the company outlines its future ahead of splitting in two next year.

“Our ultimate goal is always a cure of HIV,” Kimberly Smith, head of research and development at Glaxo’s HIV arm Viiv Healthcare, told investors in a presentation on the business Monday. I hope “that we’ll contribute to getting there by 2030 if not sooner.”

The goal was among several set out at the event, one of several investor briefings as the company prepares to spin-off its consumer unit in 2022. Glaxo set out its longterm HIV pipeline and ambitions for shareholders, and tried to quell concerns over the patent expiration of one of its key HIV drugs, dolutegravir, in 2029. The drug the company is eyeing as a potential cure is set to go into human trials next year, Smith said.